Patents by Inventor Xiaoqian XUE

Xiaoqian XUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251027
    Abstract: The present application relates to a benzidine compound and an application thereof, the benzidine compound having the structure as shown in formula I below. Further provided in the present application are a pharmaceutically acceptable salt, isomer, racemate, prodrug co-crystal complex, hydrate, and solvate of the compound, as well as an application thereof in the preparation of a drug for the treatment or prevention of ROR?-regulated diseases; more importantly, such a compound can also be used in the preparation of a drug for the treatment of inflammation, immune diseases, cancer and neurological diseases.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 11, 2022
    Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    Inventors: Yong Xu, Yan Zhang, Xishan Wu, Xiaoqian Xue, Xiaoyu Luo, Yudan Shi, Rui Wang
  • Publication number: 20210161837
    Abstract: The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
    Type: Application
    Filed: June 30, 2020
    Publication date: June 3, 2021
    Applicants: The Regents of the University of California, Guangzhou Institutes of Biomedicine and Health, U.S. Government represented by the Department of Veterans Affairs
    Inventors: Hongwu Chen, June X. Zou, Junjian Wang, Demin Cai, Yong Xu, Xiaoqian Xue, Yan Zhang
  • Publication number: 20190192454
    Abstract: The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 27, 2019
    Applicants: The Regents of the University of California, Guangzhou Institutes of Biomedicine and Health, U.S. Government represented by the Department of V eterans Affairs
    Inventors: Hongwu Chen, June X. Zou, Junjian Wang, Demin Cai, Yong Xu, Xiaoqian Xue, Yan Zhang
  • Patent number: 10183010
    Abstract: The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof. The compound and pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate, and solvate thereof can effectively inhibit the BET bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell proliferative disorders, inflammatory diseases, and autoimmune disorders, sepsis, and viral infections.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: January 22, 2019
    Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Yong Xu, Xiaoqian Xue, Yan Zhang, Ming Song
  • Publication number: 20180008574
    Abstract: The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof. The compound and pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate, and solvate thereof can effectively inhibit the BET bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell proliferative disorders, inflammatory diseases, and autoimmune disorders, sepsis, and viral infections.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 11, 2018
    Inventors: Yong XU, Xiaoqian XUE, Yan ZHANG, Ming SONG